WHAT IS CLAIMED:

1. An antibody drug conjugate comprising an anti-prostate specific membrane antigen antibody (anti-PSMA) comprising a heavy chain sequence set forth in SEQ ID NO: 8 and the light chain sequence set forth in SEQ ID NO: 9, wherein the drug linker is conjugated to position A114 according to the Kabat numbering scheme of the heavy chain sequence via a para-acetyl phenylalanine, and wherein the drug-linker is a non-cleavable monomethyl auristatin F having the structure:



2. A pharmaceutical composition comprising the antibody drug conjugate of claim 1 and at least one pharmaceutically acceptable adjuvant, binder, buffer, carrier, diluent or excipient.

3. The pharmaceutical composition of claim 2 further comprising a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

4. The pharmaceutical composition of claim 3 wherein the additional therapeutic agent is a hormonal agent.

5. The pharmaceutical composition of claim 4, wherein the hormonal agent is enzalutamide.

6. The antibody drug conjugate of claim 1 or the pharmaceutical composition of any one of claims 2 to 5 for use in therapy.

7 The antibody drug conjugate of claim 1 or the pharmaceutical composition of claim 2 for use in reducing or inhibiting tumor growth or progression in a PSMA-expressing cancer or cancer cell.

8. The pharmaceutical composition of any one of claims 3 to 5 for use in reducing or inhibiting tumor growth or progression in a PSMA-expressing cancer or cancer cell.

9. The antibody drug conjugate of claim 1 or the pharmaceutical composition of claim 2 for use in combination with an effective amount of an additional therapeutic agent to reduce or inhibit tumor growth or progression in a PSMA-expressing cancer or cancer cell.

10. The antibody drug conjugate or pharmaceutical composition for use according to claim 9, wherein the additional therapeutic agent is a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

11. The antibody drug conjugate or pharmaceutical composition for use according to claim 10, wherein the additional therapeutic agent is a hormonal agent.

12. The antibody drug conjugate or pharmaceutical composition for use according to claim 11, wherein the hormonal agent is enzalutamide.

13. Use of the antibody drug conjugate of claim 1 or the pharmaceutical composition of claim 2 in the preparation of a medicament for reducing or inhibiting tumor growth or progression in a PSMA-expressing cancer or cancer cell.

14. The use of claim 13, wherein the reducing or inhibiting tumor growth or progression in a PSMA-expressing cancer or cancer cell comprises contacting the PSMA-expressing cancer or cancer cell with an effective amount of an additional therapeutic agent.

15. The use of claim 14, wherein medicament comprises an effective amount of the additional therapeutic agent.

16. The use of claim 14, wherein the PSMA-expressing cancer or cancer cell is contacted with the additional therapeutic agent separate to the medicament.

17. The use of any one of claims 14 to 16, wherein the additional therapeutic agent is a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

18. The use of claim 17 wherein the additional therapeutic agent is a hormonal agent.

19. The use of claim 18, wherein the hormonal agent is enzalutamide.